Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 1134 participantsModerate